If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

Share Price is delayed by 15 minutes
Get Live Data
26.50    0.00 (0.00%)
Bid:
26.00
Ask:
27.00
Spread: 1.00 (3.846%)
Market Cap: £133.43m
DUKE Live PriceLast checked at - London Stock Exchange

Intraday Duke Capital Share Chart

Trading and Operational Update

31 Mar 2026 07:00

RNS Number : 7112Y
Duke Capital Limited
31 March 2026
 

31 March 2026

Duke Capital Limited

 

("Duke Capital", "Duke" or the "Company")

 

Trading and Operational Update

 

Duke Capital Limited (AIM: DUKE), a leading provider of hybrid capital solutions for SME business owners in Europe and North America, is pleased to provide guidance on its trading for the fourth quarter of the financial year ending 31 March 2026 ("Q4 FY26").

 

Trading Update

 

Duke expects to achieve record recurring cash revenue* of £7.0 million in Q4 FY26. This represents an 8% year-on-year increase on Q4 FY25 (£6.5 million) and an increase of £0.2 million over the prior quarter, which saw the Company deliver recurring cash revenue of £6.8 million.

 

Total cash revenue for Q4 FY26 is expected to total £8.5 million following receipt of the final tranche of deferred consideration from the Fabrikat exit in February 2024.

 

Overview of quarterly revenue growth:

 

 

Recurring Cash Revenue*

Total Cash Revenue**

Q4 FY25

£6.5 million

£6.5 million

Q1 FY26

£6.6 million

£6.6 million

Q2 FY26

£6.6 million

£6.6 million

Q3 FY26

£6.8 million

£6.8 million

Q4 FY26 forecast

£7.0 million

£8.5 million

 

* Recurring cash revenue excludes exit premium receipts and cash gains from equity sales

** Total cash revenue is monthly cash distributions from Duke's partners plus exit premium receipts and cash gains from equity sales

 

Fabrikat exit

 

· Duke invested £6.2 million into Fabrikat in February 2021 and received £3.2 million in distributions until the sale of the company in March 2024 to Metalogalva - Irmãos Silvas, SA, a Portuguese company in the area of engineering and steel protection.

· Upon sale, Duke received total proceeds of £11.4 million, including £1.5 million in deferred payments, which resulted in a 35% IRR over a five-year period.

 

Neil Johnson, CEO of Duke Capital, said:

 

"We are delighted to report another record quarter of recurring cash revenue for Q4 FY26, rounding off a strong finish to the financial year. This performance reflects the resilience of our business model in navigating a challenging macroeconomic environment. Whilst the Bank of England's decision to hold rates in March reflects the ongoing uncertainty in global markets, including the situation in the Middle East, our business model has demonstrated its ability to perform across market cycles.

 

"The receipt of the final deferred consideration from the Fabrikat exit demonstrates our ability to provide upside for shareholders upon exits. While exits are expected in our business model, the timing of them is dependent on the broader fundraising environment. We are pleased to show both the resilience of our recurring revenue and upside from exits in the current quarter, and we look forward to updating shareholders further in our annual results."

 

 

***ENDS***

 

For further information, please visit https://dukecapital.com/ or contact:

 

Duke Capital Limited

Neil Johnson / Charles Cannon Brookes / Hugo Evans

 

+44 (0) 1481 231 816

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Stephen Keys / Callum Davidson / Michael Johnson 

+44 (0) 207 220 0500

 

Canaccord Genuity Limited

(Joint Broker)

 

Adam James / Harry Rees

+44 (0) 207 523 8000

SEC Newgate (Financial Communications)

Robin Tozer / Alice Cho / Gwen Samuel

+ +44 (0) 20 3757 6882 dukecapital@secnewgate.co.uk

 

 

About Duke Capital

 

Duke is a leading provider of hybrid capital solutions for SME business owners in Europe and North America, combining the best features of both equity and debt.

 

Since 2017, Duke has provided unique long-term financing which eliminates re-financing risk and necessity for a short-term exit by providing a unique 'corporate mortgage' while also aligning its returns to grow with the success of the business.

 

Duke is focused on generating attractive risk-adjusted returns for shareholders and has a track record of achieving this across market cycles. Its three investment pillars are capital preservation, attractive dividend yield, and to provide upside upon exits.

 

Duke is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTAKKBQFBKDCNN
Date   Source Headline
27th May 20229:08 amRNSDirector / PCA Dealings
26th May 20223:23 pmRNSResult of General Meeting and Issue of Equity
11th May 20227:05 amRNSRaises £20m through Placing and PrimaryBid Offer
10th May 20225:08 pmRNSPrimaryBid Offer
10th May 20224:44 pmRNSPlacing to raise a minimum of £15 million
28th Apr 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
20th Apr 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
11th Apr 20227:00 amRNSTrading Update
18th Mar 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
17th Mar 20227:00 amRNSIncreased Interim Dividend & Dividend Declaration
2nd Mar 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
25th Feb 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
17th Feb 20227:00 amRNSFurther re: Directorate Change
14th Feb 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
2nd Feb 20227:00 amRNSDirectorate Changes
1st Feb 202210:02 amRNSReplacement - Trading Update
1st Feb 20227:00 amRNSTrading Update
20th Jan 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
23rd Dec 20212:30 pmRNSHolding(s) in Company
23rd Dec 20217:01 amRNSTrading Update
23rd Dec 20217:00 amRNSFollow-on investment into existing Royalty Partner
22nd Dec 20213:52 pmRNSFollow-on investment into existing Royalty Partner
16th Dec 20217:00 amRNSNew Royalty Agreement
14th Dec 20217:00 amRNSIncreased Interim Dividend & Dividend Declaration
7th Dec 20217:00 amRNSEnters into Largest Royalty Agreement To Date
3rd Dec 20217:00 amRNSInterim Results
2nd Dec 20217:00 amRNSCompletion of £4.2 million Follow-On Investment
25th Nov 20217:00 amRNSNotice of Interim Results
29th Oct 20214:03 pmRNSLong Term Incentive Plan Awards
27th Oct 20217:01 amRNSFollow-On Investment into Existing Royalty Partner
27th Oct 20217:00 amRNSHolding(s) in Company
22nd Oct 20214:36 pmRNSResult of Annual General Meeting
16th Sep 20217:01 amRNSInterim Dividend and Dividend Declaration
16th Sep 20217:00 amRNSFinal Results
7th Sep 20217:00 amRNS£2.2m Follow-On Investment into Royalty Partner
2nd Sep 20217:00 amRNSHolding(s) in Company
17th Aug 20217:00 amRNSInvestor Presentation
11th Aug 20217:00 amRNSSuccessful Exit of Investment in Royalty Partner
10th Aug 20217:00 amRNSNotice of Results and Analyst Presentation
2nd Aug 20217:00 amRNSNew Royalty Agreement
26th Jul 20217:00 amRNSTrading Update
22nd Jul 20217:00 amRNSNew Royalty Agreement
1st Jul 20217:00 amRNSNew Royalty Agreement with Fairmed Healthcare AG
17th Jun 20217:00 amRNSInterim Dividend and Dividend Declaration
10th May 20217:00 amRNSTrading Update
20th Apr 20215:22 pmRNSHolding(s) in Company
20th Apr 20215:19 pmRNSHolding(s) in Company
20th Apr 20214:19 pmRNSHolding(s) in Company
19th Apr 202112:30 pmRNSDirector / PCA Dealings
19th Apr 20217:00 amRNSSuccessful Exit of Investment in Royalty Partner

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.